Endothelin antagonism with bosentan: current status and future perspectives

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Endothelin System Biology

Background:

• Endothelins are implicated in pathogenic processes of cardiovascular diseases.
• Endothelin receptor antagonists (ERAs) offer a therapeutic strategy for these conditions.
• Bosentan is a nonpeptide competitive antagonist targeting both endothelin receptors A and B.

Purpose of the Study:

• To provide an overview of the experimental and clinical effects of bosentan.
• To highlight bosentan's role as a tool for studying the endothelin system.
• To discuss the therapeutic potential of bosentan in cardiovascular and other disorders.

Main Methods:

• Review of preclinical studies on bosentan's mechanism of action.
• Analysis of clinical trial data, including Phase III trials.
• Examination of bosentan's specificity for endothelin receptors.

Main Results:

• Bosentan effectively blocks endothelin actions at both ETA and ETB receptors.
• Experimental data suggest potential benefits in conditions like hypertension and heart failure.
• Clinical development has advanced to Phase III, indicating promising therapeutic potential.

Conclusions:

• Bosentan is a valuable pharmacological tool for investigating the endothelin system.
• Its dual receptor antagonism and progression to Phase III trials underscore its therapeutic promise.
• Further clinical evaluation is crucial to establish the full spectrum of bosentan's efficacy and safety.